Third patient dosed in Phase 1/2 SMD trial using RPE cells derived from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

Full Story →